Business
enVVeno Medical Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
On-demand video webcast now available here IRVINE, CA / ACCESS Newswire / February 19, 2025 /enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today ...
About this update from Envveno Medical Corporation
[{"type":"text","content":"On-demand video webcast now available here","length":42,"tagName":"p"},{"type":"text","content":"IRVINE, CA / ACCESS Newswire / February 19, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced it participated in the Virtual Investor "Top 5 for ‘25" On-Demand Conference.","length":323,"tagName":"p"},{"type":"text","content":"As part of the event, Robert Berman, Chief Executive Officer of enVVeno, presented the top five reasons of why he believes the investment community and industry colleagues should pay attention to the Company in 2025.","length":216,"tagName":"p"},{"type":"text","content":"The on-demand video webcast is now accessible for viewing here and on the Events page in the Investors section of the Company's website (envveno.com).","length":154,"tagName":"p"},{"type":"text","content":"About enVVeno Medical Corporation","length":33,"tagName":"p"},{"type":"text","content":"enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company's lead product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous Chronic Venous Insufficiency (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe®. CVI occurs when valves inside of the veins of the leg become damaged, resulting in the backwards flow of blood (reflux), blood pooling in the lower leg, increased pressure in the veins of the leg (venous hypertension) and in severe cases, venous ulcers that are difficult to heal and become chronic. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve is currently being evaluated in the SAVVE U.S. pivotal study and the Company is currently performing the final testing necessary to seek approval for the pivotal trial for enVVe.","length":1225,"tagName":"p"},{"type":"text","content":"Cautionary Note on Forward-Looking Stateme...